drugset / Trial / NCT04191577
Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a phase 2 study, randomized, double-blind, placebo-controlled, multicenter study of oral CVN424 at two dose levels (low-dose and high-dose) in Parkinson's disease (PD) patients with motor fluctuations.
Timeline
- Start
- 2019-12-02
- Primary completion
- 2021-11-06
- Completion
- 2021-12-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | SOLENGEPRAS | Small molecule | — | Oral |